INDV at a glance
Indivior Pharmaceuticals, Inc. (INDV, SEC CIK 1625297) filed its latest 20-F annual report on March 6, 2024 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Indivior Pharmaceuticals, Inc. (INDV) reported revenue of $1.2 billion (up 4.3% from FY2024) and net income of $210.0 million. Diluted EPS was $1.64.
- As of September 30, 2026, 31 institutional investment managers tracked by SignalX reported holding Indivior Pharmaceuticals, Inc. (INDV) shares worth $2.2 billion in 13F-HR filings.
- In the last 90 days, INDV insiders reported 1 open-market purchase ($54K) and 0 open-market sales ($0) on Form 4, a net purchase of $54K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.2B
- +4.3% vs prior year
- Insiders · 90 days
- 1 buy · 0 sells
- Net +$54K
- 13F holders
- 31 funds
- $2.2B · −1 vs prior quarter
- Latest 8-K
- Nov 3, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Pending Supernus merger subject to stockholder and regulatory approvals, with completion timing uncertain
- Merger failure risk includes substantial termination fee exposure and transaction costs
- Contractual restrictions during merger could limit acquisitions, indebtedness, dividends, capital expenditures, and claim settlements
- Fixed 1.5401 exchange ratio exposes Indivior shareholders to stock-price volatility before closing
- Integration risk could prevent realization of anticipated merger synergies, growth, profitability, and earnings accretion
AI summary of the INDV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Special Dividend triggered an adjustment to the 0.625% convertible notes due 2031
- Conversion rate increased from 24.0033 to 30.9355 shares per $1,000 principal
Item 2.03: Creation of a Direct Financial Obligation
- Item 2.03 links to Item 1.01, indicating a newly created direct financial obligation tied to a material agreement
- Investor impact depends on the borrowing amount, pricing, maturity and repayment terms disclosed under Item 1.01
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Corporate name changed from Indivior Pharmaceuticals, Inc. to Supernus, Inc. upon merger completion
- Nasdaq ticker changing from INDV to SUPN around November 3, 2026
Item 1.01: Entry into a Material Definitive Agreement
- $650M senior secured term loan fully drawn November 2, 2026 to fund the merger, refinance debt, transaction costs and corporate purposes
- Initial pricing: Term SOFR plus 2.25% or Base Rate plus 1.25%, at company election
Item 7.01: Regulation FD Disclosure
- Indivior announced completion of the merger, marking the transaction’s closing and transition to combined-company operations
- Merger completion may affect ownership, capital structure, reporting, and strategic priorities going forward
Item 2.01: Completion of Acquisition or Disposition of Assets
- Indivior completed its merger with Supernus, creating a combined company with former Supernus holders receiving Indivior equity
- Exchange ratio: 1.5401 Indivior shares per Supernus share, with cash paid for fractional shares
Item EX-99.1: Item EX-99.1
- Merger closed, creating Supernus, Inc., an 11-product CNS platform spanning opioid use disorder, psychiatry, and neurology
- Indivior shareholders receive a $1.0 billion aggregate special dividend, funded partly by a $650 million Citibank term loan
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Merger-driven leadership reset: Indivior’s CEO, CFO, commercial chief and legal chief departed at closing
- CEO Joseph Ciaffoni separation payments total $3,345,000, plus 18 months of health benefits and full RSU vesting
Item 2.02: Results of Operations and Financial Condition
- Fiscal period ended September 30, 2026, covering Indivior’s third quarter results
- Results furnished in Exhibit 99.1, the company’s press release
Item EX-99.1: Item EX-99.1
- Q3 revenue $356M, up 13% YoY, led by SUBLOCADE revenue $267M, up 22%
- Record adjusted EBITDA $211M, up 76%, with margin 59%, up 2,100 basis points
AI summaries of INDV 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for INDV
Don't miss the next INDV filing
- Alerts as it files. A push when INDV files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut INDV, by share count.
- Ask anything. An AI agent that reads every INDV filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Mottola Frank | J | Nov 2, 2026 | 30,802 | - |
| Mottola Frank | J | Nov 2, 2026 | 20,791 | - |
| Mottola Frank | J | Nov 2, 2026 | 38,502 | - |
| Mottola Frank | J | Nov 2, 2026 | 46,203 | - |
| Mottola Frank | J | Nov 2, 2026 | 30,099 | - |
| Mottola Frank | J | Nov 2, 2026 | 21,561 | - |
| Mottola Frank | J | Nov 2, 2026 | 26,181 | - |
| Mottola Frank | J | Nov 2, 2026 | 33,882 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.2B | $1.2B |
| Gross Profit | - | $957.0M | $994.0M |
| Operating Income | - | $32.0M | $262.0M |
| Net Income | - | $2.0M | $210.0M |
| Gross Margin | - | 80.6% | 80.2% |
| Op. Margin | - | 2.7% | 21.1% |
| Net Margin | - | 0.2% | 16.9% |
| Balance Sheet | |||
| Total Assets | - | $1.3B | $1.2B |
| Equity | - | -$348.0M | -$98.0M |
| ROE | - | -0.6% | -214.3% |
| Per Share | |||
| EPS | $-0.94 | $0.02 | $1.64 |
| Cash Flow | |||
| Operating CF | - | $36.0M | -$27.0M |
| CapEx | $8.0M | $29.0M | $66.0M |
Source: XBRL data in Indivior Pharmaceuticals, Inc. (INDV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate INDV share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 31 | $2.25B |
| Q2 2026 | 32 | $2.59B |
| Q1 2026 | 32 | $1.91B |
- Millennium Management+4.18M (+199%)
- Goldman Sachs Group+747.8K (+107%)
- Citadel Advisors LLC+478.0K (+18%)
- Prudential Financial+341.2K (+130%)
- Morgan Stanley+246.6K (+7%)
- Franklin Resources−1.67M (-50%)
- Mangrove Partners−1.54M (-58%)
- Invesco Ltd−642.3K (-35%)
- Citigroup−615.2K (-96%)
- Vanguard Portfolio Management LLC−585.7K (-8%)
- FMR LLC (Fidelity)−402.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 95 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
INDV filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 20-F, 6-K
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 8-K | Oct 15, 2026 | - | Analysis | - |
| 8-K | Oct 6, 2026 | - | Analysis | - |
| 8-K | Sep 17, 2026 | - | Analysis | - |
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 4 | Aug 27, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 4 | Jul 13, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
INDV SEC filings: frequently asked questions
Are INDV insiders buying or selling?
In the last 90 days, Indivior Pharmaceuticals, Inc. (INDV) officers, directors and 10% owners reported 1 open-market purchase worth $53,535 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold INDV stock?
As of September 30, 2026, the largest Indivior Pharmaceuticals, Inc. (INDV) holders among the 13F filers tracked by SignalX were BlackRock ($668.0 million), Vanguard Portfolio Management LLC ($250.5 million), Millennium Management ($225.2 million), Vanguard Capital Management LLC ($189.8 million), State Street Corp ($180.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was INDV's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Indivior Pharmaceuticals, Inc. (INDV) reported revenue of $1.2 billion (up 4.3% from FY2024) and net income of $210.0 million. Diluted EPS was $1.64. The figures come from the XBRL data in the 10-K.
What did INDV report in its latest 8-K?
Indivior Pharmaceuticals, Inc. (INDV) filed an 8-K on November 3, 2026 reporting Item 8.01 (Other Events). Special Dividend triggered an adjustment to the 0.625% convertible notes due 2031.
What are the latest INDV SEC filings?
Indivior Pharmaceuticals, Inc. (INDV) filed its latest 20-F annual report on March 6, 2024 and a Form 4 insider filing on November 4, 2026.
What is INDV's SEC CIK number?
Indivior Pharmaceuticals, Inc. (INDV)'s SEC Central Index Key (CIK) is 1625297. EDGAR lists every INDV filing under that number.
Ask anything about INDV
The research agent reads INDV's filings, financials, insider trades and 13F holders, then answers with sources.